Great benefits of using semaglutide in our treatment
In early 2021 Semaglutide (Wygovy) was approved by the FDA for chronic weight loss. Participants in the trial reported weight loss ranging from 15% to 18% of their body weight in a year. Since then, we have been applying Semaglutide as a weapon to combat obesity and helping to lose unwanted body fat other which felt otherwise almost impossible for many people. The benefits include:
- Reduced blood sugar due to the optimized release of insulin from the pancreas
- Reducing appetite and feeling of hunger
- By slowing down the digestion of food, you can make your stomach feel full more quickly